CAS 87805-34-3|GLP-1 (1-37) (human, bovine, guinea pig, mouse, rat) trifluoroacetate salt
Introduction：Basic information about CAS 87805-34-3|GLP-1 (1-37) (human, bovine, guinea pig, mouse, rat) trifluoroacetate salt, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | GLP-1 (1-37) (human, bovine, guinea pig, mouse, rat) trifluoroacetate salt | ||
|---|---|---|---|
| CAS Number | 87805-34-3 | Molecular Weight | 4169.48 |
| Density | / | Boiling Point | / |
| Molecular Formula | C186H275N51O59 | Melting Point | / |
| MSDS | USA | Flash Point | / |
Names
| Name | GLP-1 (1-37) amide |
|---|---|
| Synonym | More Synonyms |
BiologicalActivity
| Description | Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor. |
|---|---|
| Related Catalog | Signaling Pathways >>GPCR/G Protein >>Glucagon ReceptorPeptidesResearch Areas >>Metabolic Disease |
| Target | GLP-1 receptor[1] |
| In Vitro | Glucagon-like peptide-1 (GLP-1) is produced by the posttranslational processing of proglucagon and acts as a regulator of various homeostatic events. GLP-1(1-37) is more stable than GLP-1(7-37), with 94.7% of the initial amount of peptide left after a 4h exposure to mouse serum. GLP-1(1-37) is confirmed to be a highly potent agonist of the GLP-1 receptor (GLP-1R) by measuring the expression of the luciferase reporter gene expression in transiently transfected human embryonic kidney (HEK293) cells[1]. |
| In Vivo | GLP-1(1–37) decreased glycemic excursion in a dose-dependent. The administration of GLP-1(1–37) or GLP-1(7–37) markedly decrease blood glucose levels at 15 min and 30 min compared with the control group[1]. |
| Cell Assay | HEK293 cells (5×104) are seeded in a 96-well plate and transiently cotransfected with the GLP-1R plasmid and the CRE-luciferase reporter plasmid. After a 48 h transfection, different concentrations of GLP-1(1–37) or GLP-1(7–37) are added, and the cells are incubated for 5 h. The cells are harvested for a luciferase assay using a luciferase assay[1]. |
| Animal Admin | Mice[1] The normal KM mice are fasted for 16 h before the administration (i.p.) of GLP-1 and glucose. GLP-1(1-37) (25 nmol/kg) with or without exendin(9-39) (250 nmol/kg) is given in combination with glucose (4 g/kg). GLP-1(7-37) (25 nmol/kg) with or without exendin(9-39) (250 nmol/kg) is also administrated in combination with glucose (4 g/kg). The control group is treated with saline (NaCl, 9 g/l) and glucose (4 g/kg). The IPGTT is carried out at 0, 15, 30 and 60 min after glucose and protein administration, and the blood glucose levels are measured as described above[1]. |
| References | [1]. Zhao L, et al. Glucagon-like peptide-1(1-37) can enhance blood glucose homeostasis in mice. Regul Pept. 2012 Oct 10;178(1-3):1-5. |
Chemical & Physical Properties
| Molecular Formula | C186H275N51O59 |
|---|---|
| Molecular Weight | 4169.48 |
| InChIKey | UKVFVQPAANCXIL-FJVFSOETSA-N |
| SMILES | CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCN)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(Cc1cnc[nH]1)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)O)NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(=O)NC(CCCCN)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C |
| Storage condition | −20°C |
Safety Information
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
Articles5
More Articles| GLP-1-related proteins attenuate the effects of mitochondrial membrane damage in pancreatic β cells. Biochem. Biophys. Res. Commun. 447(1) , 133-8, (2014) Glucagon-like peptide (GLP)-1 analog based therapies are used not only for their insulinotropic effects, but also for their pleiotropic effects that improve pancreatic β cell function. Liraglutide is ... | |
| Glucagon-like peptide-1 and blood pressure in young and healthy adults from the general population. Hypertension 65(2) , 306-12, (2015) Hypertension and diabetes mellitus are highly correlated, but the underlying mechanisms are only partly understood. Therefore, the aim of our study was to investigate the relationships between plasma ... | |
| The low level of glucagon-like peptide-1 (glp-1) is a risk factor of type 2 diabetes mellitus. BMC Res. Notes 7 , 849, (2014) Glucagon like peptide-1 (GLP-1), an incretin hormone, regulates glucose metabolism by inducing insulin secretion and suppressing glucagon secretion. The aim of the study is to assess the levels of fas... |
Synonyms
| Glucagon-like peptide 1 (1-37) |
| Glucagon-like peptide 1 (1-37) (human, rat) |
| Glucagon-like peptide 1 (1-37), human |
